Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JY040
- Development stage
- Preclinical
- Lead developer
- Beijing Dongfang Baitai Biotechnology
01
Overview
JY040 is a preclinical-stage biological drug candidate being developed by Beijing Dongfang Baitai Biotechnology (Beijing Oriental Biotech) for the treatment of autoimmune diseases. While specific details regarding its molecular target and mechanism of action remain undisclosed, the developer specializes in the research and development of innovative monoclonal antibodies, bispecific antibodies, and fusion proteins targeting major therapeutic areas including oncology, diabetes, and immunology.
Beyond the preview
Go deeper on JY040.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JY040.